Navigation Links
Medarex Announces Ipilimumab Program Continues to Move Forward
Date:4/3/2008

24 Phase 3 trial by the Data Monitoring Committee (DMC) indicated that our trial should continue.

Finally, we and our partner, Bristol-Myers Squibb Company, continue to move firmly forward. Our previously-stated guidance remains unchanged and regulatory discussions are pending."

About the Chemotherapy Combination Registrational Trial

Study 024 is a randomized, blinded registrational Phase 3 study designed to evaluate the effect of dacarbazine in combination with 10mg/kg ipilimumab or placebo on progression-free survival and overall survival in 500 patients with previously untreated metastatic melanoma (front-line). Ipilimumab is administered at 10 mg/kg once every three weeks for up to four doses. Subsequently, eligible patients who have not experienced disease progression at week 24 will continue in a maintenance phase where a single dose of ipilimumab or placebo will be administered once every 12 weeks until disease progression. All efficacy analyses, except for overall survival and survival rate at one year, will be conducted when at least 416 events for progression- free survival have been observed in the study and all patients have been followed for at least 12 weeks.

In June 2006, the 024 registrational Phase 3 trial was reviewed by the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) concerning the suitability of the trial design to support regulatory approval. In December 2006, the FDA granted Fast Track status to this program which provides for expedited regulatory review for new drugs that demonstrate the potential to address unmet medical needs for the treatment of serious or life-threatening conditions. Trial enrollment was completed in the first- quarter of 2008.

About Ipilimumab

Ipilimumab is a fully human antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that plays a critical role in regulating natural immune responses. The absen
'/>"/>

SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Medarex Announces Allowance of Investigational New Drug Applications for Wholly Owned Fully Human Anti-CD19 Antibody, MDX-1342
2. Medarex to Receive Milestone Payment from Amgen
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
5. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
6. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
7. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
8. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
9. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
10. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
11. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2, 2015  Boca Raton Regional Hospital,s ... performing ultra-minimally invasive left atrial appendage ligation for ... as Coumadin, Xarelto or Effient. Dr. Cartledge, who ... is one of a select group of surgeons ... microscopic incisions in order to seal off the ...
(Date:9/2/2015)... , September 2, 2015 According ... by Product (Digital & Computed Radiography, Ultrasound, Computed & ... PACS) by Application (Oncology, Cardiology, Neurology) - Global Forecast ... to reach USD 2.8 Billion by 2020 growing at ... Br owse 240 Tables and 44 ...
(Date:9/2/2015)... Md. , Sept. 2, 2015  RegeneRx ... a clinical-stage drug development company focused on tissue ... J.J. Finkelstein , President and Chief Executive Officer, ... & Renshaw Global Investment Conference, sponsored by ... be held September 8-10, 2015 at the St. ...
Breaking Medicine Technology:Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3Veterinary Imaging Market Worth USD 2.8 Billion by 2020 2Veterinary Imaging Market Worth USD 2.8 Billion by 2020 3Veterinary Imaging Market Worth USD 2.8 Billion by 2020 4Veterinary Imaging Market Worth USD 2.8 Billion by 2020 5RegeneRx to Present at Rodman & Renshaw Global Investment Conference 2RegeneRx to Present at Rodman & Renshaw Global Investment Conference 3
... facilities are facing unprecedented challenges due to current economic ... budgets and lowered staffing levels, has forced facilities to ... purchasing surgical instruments . A focus on quality, ... price. Most US-based surgical instrument suppliers do ...
... 2011 Mettler-Toledo International Inc. (NYSE: MTD ) ... the Company,s third-quarter results on Thursday, November 3, 2011 at ... the call, visit www.mt.com/investors on the Company,s website. ... 7, 2011. METTLER TOLEDO is a leading ...
Cached Medicine Technology:American-Made Surgical Instruments Meet the High Demands of Surgical Facilities 2
(Date:9/2/2015)... ... ... A recent survey by Consumer Reports ( http://bit.ly/1h67tL8 ) sheds light on ... consumers. It was reported that 33% are paying an average of $39 more out-of-pocket ... $100 compared to last year. Among the drugs that saw the highest increases were ...
(Date:9/2/2015)... ... September 02, 2015 , ... Based in Chicago, and with ... as an industry leader specializing in surplus used medical equipment auctions. They are ... pieces of medical equipment every year. Erik Tivin, Chairman and CEO, is regarded ...
(Date:9/2/2015)... ... September 02, 2015 , ... Lakeview Health, a nationally recognized ... Overdose Awareness Day. The goal is to provide people information regarding drugs and ... they may get help. , Lakeview Health will be publishing information ...
(Date:9/2/2015)... ... 02, 2015 , ... Please join the world renowned Brain ... was established by the Foundation in 2007 with the help of Massachusetts State ... research remains our top priority,” commented Christine Buckley, Executive Director of the Brain ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... ahead of Breast Cancer Awareness Month (BCAM), Bright Pink, a national non-profit focused ... women, will launch Act On Facts, a campaign to educate women to be ...
Breaking Medicine News(10 mins):Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 2Health News:Over 1800 Lots of Surplus Used Medical Equipment 3Health News:August 31 is International Overdose Awareness Day – Lakeview Health to Help Bring Awareness 2Health News:September Celebrated as Brain Aneurysm Awareness Month 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 2Health News:Bright Pink Launches Act On Facts™, A Campaign To Empower Young Women To Take Action Related To Their Breast And Ovarian Health 3
... the Table, Campaign To Provide Food and Cash ... Donations To Local Food Banks, ... in,the fight against hunger, Food 4 Less, a division of The ... a two-week,campaign running this month in every store to support America,s ...
... revive unconscious passenger, SACRAMENTO, Calif., June 10 ... the life of a 53-year-old,passenger on their Southwest ... The trio was among a group of 35 ... attend a contract bargaining session with their,employer, Catholic ...
... Perot Systems on the Impact of ... Technology in Healthcare, PLANO, Texas, June ... Executive Vice President, International Healthcare ... Humana, Perot Systems continues its ...
... Targeted Therapy Reduces Chemoresistance in Mouse Model of Melanoma ... endogenous and drug-induced resistance to chemotherapy in a mouse ... active in human cancers and promotes resistance to cytotoxic ... NF-κB pathway activity. , To determine if a new ...
... Ohio Viruses genetically designed to kill cancer cells ... such as glioblastoma, but the body,s natural defenses often ... The findings of an animal study by researchers at ... why this happens and could improve this therapy for ...
... encourage disease/prevention efforts , , TUESDAY, June 10 (HealthDay News) -- ... of dying then women, and smoking increases any adult,s risk ... to their age, according to new risk of death charts. ... online issue of the Journal of the National Cancer ...
Cached Medicine News:Health News:Food 4 Less Continues Fight to Help End Hunger in America 2Health News:Food 4 Less Continues Fight to Help End Hunger in America 3Health News:UHW Members Save Man's Life On Flight 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 2Health News:Healthcare Tech and the World: A New Perspective on Innovation in Healthcare 3Health News:Also in the June 10 JNCI 2Health News:Cancer-killing viruses influence tumor blood-vessel growth 2Health News:Researchers Update Risk-of-Death Charts 2
The sterile cardiac blanket is utilized during surgical procedures that require access to the upper half of the body. Warms groin area while providing easy access to the area through a perforated ope...
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
The adult underbody blanket is conveniently positioned on the table before the patient arrives to the procedure suite....
The cardiac access blanket helps maintain normothermia and allows unrestricted access to the patient....
Medicine Products: